- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01738295
Donepezil Effect on Visual Attention and Training
Donepezil Effect on Visual Attention and Perceptual Training in Healthy Young Adults
The present proposal investigates the role of the cholinergic system (the neurotransmitter acetylcholine) in improving vision and visual attention. Vision results from a complex processing of particular stimuli of the visual field. Attention enhances and prolongs the neural representations of visual input in the visual cortex. It has recently been shown that attention in the visual cortex depends on cholinergic mechanisms. The action of acetylcholine in the visual cortex consists in enhancement of the responsiveness to thalamocortical inputs, depression of local neuronal connections or extrastriate feedback projections and induction of gamma synchronisation. The investigators hypothesize that these effects are associated with long-term changes in functional connectivity in the visual cortex, visual attention and visual learning (improvement of the visual capacities).
In the present proposal, the investigators will test whether the administration of donepezil (Aricept, 5mg), a drug that increases the level of acetylcholine in the brain, will enhances the perceptual-cognitive abilities of young adult subjects. Perceptual-cognitive performance will be assessed in a multiple object tracking (MOT) task in a 3D automatic virtual environment. MOT is a task where observers are asked to maintain attentional focus on a limited number of preselected subgroup of elements in a dynamic scene. Multifocal attentional mechanisms are necessary to process the information. The task will be tested five time at one week interval to test whether donepezil and training improved the task performance of the subject, i.e. lead to perceptual learning. This study could help establish an intervention procedure to improve visual performance of subjects that need it.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Stages of a given perceptual-cognitive task (from Faubert and Sidebottom, Journal of Clinical Sport Psychology, 2012, 6, 85-102):
- a predetermined number of spheres (typically eight) are presented in a 3D dimensional virtual volumetric cube space. The spheres are typically all identical.
- a subset of spheres (typically four) is indexed via highlighting for a brief period of 1 s.
- the spheres return to their original color and start moving within the restricted 3D virtual space. During this movement, the spheres can collide and consequently suddenly change direction, and they can cross over others, thus occluding their view.
- the spheres stop moving after a predetermined time, and the observer has to identify the spheres that were initially indexed with halos. The subject is then given feedback on the response by having the spheres identified by revealing the appropriate indexed stimuli.
The main task starts at a given speed, and if all four spheres are not correctly identified, the next trial will be slower. If the four spheres are correctly identified, then the next trial will be faster. Trials are repeated like this following a staircase procedure, and ultimately, a speed threshold is established.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada, H3T 1P1
- School of optometry / Université de Montréal
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- good general health
- 17 < body mass index < 25
- visual acuity 6/6
- visual stereoscopy > 50
- standard visual field
Exclusion Criteria:
- pregnancy or breast feeding
- use of any drug or St John's wort
- smoking
- asthma
- pulmonary obstruction
- cardiovascular impairment
- attention troubles
- ocular diseases
- epilepsy
- lactose intolerance
- absorption of grapefruit juice
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Donepezil
Donepezil administration.
In this group Donepezil (Aricept pill, 5 mg) will be orally administrated 3h before each experiment (1 week intervals)
|
Other Names:
|
|
Placebo Comparator: Lactose pill
Placebo administration.
In this group, placebo (lactose pill) will be orally administrated 3h before each experiments (1 week intervals)
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Measure of the speed threshold, baseline
Time Frame: week 0
|
The speed of the moving spheres is increased across trials until the subject is not able anymore to track and identify the indexed spheres (speed threshold).
In this baseline task, the subject will not take Donepezil or placebo
|
week 0
|
|
Change from baseline of the speed threshold at 1 week
Time Frame: week 1
|
The speed of the moving spheres is increased across trials.
The maximal speed for which the subject is able to track and identify the indexed spheres is the speed threshold.
At this time point, the effect of Donepezil (5 mg, single dose) or placebo administration on the perceptual-cognitive performance will be assessed.
|
week 1
|
|
Change from baseline of the speed threshold at 2 weeks
Time Frame: week 2
|
The speed of the moving spheres is increased across trials.
The maximal speed for which the subject is able to track and identify the indexed spheres is the speed threshold.
At this time point, the effect of Donepezil (5 mg, single dose) or placebo administration on the perceptual-cognitive performance will be assessed.
|
week 2
|
|
Change from baseline of the speed threshold at 3 weeks
Time Frame: week 3
|
The speed of the moving spheres is increased across trials.
The maximal speed for which the subject is able to track and identify the indexed spheres is the speed threshold.
At this time point, the effect of Donepezil (5 mg, single dose) or placebo administration on the perceptual-cognitive performance will be assessed.
|
week 3
|
|
Change from baseline of the speed threshold at 4 weeks
Time Frame: week 4
|
The speed of the moving spheres is increased across trials.
The maximal speed for which the subject is able to track and identify the indexed spheres is the speed threshold.
At this time point, the effect of Donepezil (5 mg, single dose) or placebo administration on the perceptual-cognitive performance will be assessed.
|
week 4
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Elvire Vaucher, PhD, Université de Montréal
- Study Director: Jocelyn Faubert, PhD, Université de Montréal
- Principal Investigator: Isabelle Legault, PhD, Université de Montréal
- Principal Investigator: Mira Chamoun, MSc, Université de Montréal
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12-084-CERES
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
University of Vermont Medical CenterAvocado Nutrition CenterRecruitingHealthy | Healthy Volunteers | Healthy Subjects | Healthy Volunteer | Healthy Adult | Healthy Volunteers Only | Healthy Male and Female Subjects | Healthy Non-smokersUnited States
-
Dragonfly TherapeuticsRecruitingHealthy | Healthy Participants | Healthy Adult Females | Volunteer | Healthy Adult MaleAustralia
-
University of PalermoCompletedHealthy | Healthy Volunteers | Healthy Subjects | Healthy Participants | Static Stretching | Stretch | StretchingItaly
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Umm Al-Qura UniversityActive, not recruitingHealthy | Healthy Participants | Healthy Adult | Healthy Women | Healthy Adult Females | Healthy Adult Participants | Healthy Young Adults | Healthy Adult Female Participants | Healthy Adult Male | Poor Sleep Quality | Healthy (Controls) | Poor Sleeping Quality | Healthy Adult Male Subjects | Health Adult SubjectsSaudi Arabia
-
University of PalermoCompletedHealthy Participants | Healthy Adult Participants | Healthy Young AdultsItaly
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
PfizerNot yet recruitingHealthy | Healthy AdultsUnited States
-
Atisama TherapeuticsRecruitingHealthy | Healthy SmokerAustralia
Clinical Trials on Donepezil administration
-
Eisai Co., Ltd.CompletedDementia With Lewy Bodies (DLB)Japan
-
Corium, Inc.CompletedAlzheimer DiseaseUnited States
-
Centre Hospitalier St AnneInstitut National de la Santé Et de la Recherche Médicale, France; Université...Not yet recruitingAnorexia Nervosa Restricting Type
-
Eisai Inc.Eisai LimitedCompleted
-
Eisai Co., Ltd.CompletedDementia With Lewy Bodies (DLB)Japan
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloActive, not recruiting
-
Samsung Medical CenterEisai Korea Inc.CompletedDementia | Alzheimer's DiseaseKorea, Republic of
-
Shanghai Synergy Pharmaceutical Sciences Co., Ltd.Completed
-
The First Affiliated Hospital with Nanjing Medical...Unknown
-
Eisai Inc.PfizerTerminatedCognitive Dysfunction | Down SyndromeUnited States